8-K: Ontrak Secures $1.5 Million in Initial Funding, Amends Note Purchase Agreement

Ontrak, Inc. has entered into a sixth amendment to its Master Note Purchase Agreement, securing an initial $1.5 million in funding and potentially up to an additional $13.5 million, while also adjusting warrant terms.

Summary

• Ontrak, Inc. has amended its Master Note Purchase Agreement with Acuitas Capital LLC, securing an initial $1.5 million through a senior secured convertible promissory note.
• The agreement allows Acuitas to purchase up to an additional $13.5 million in principal amount of Demand Notes at its discretion.
• In connection with each Demand Note purchase, Ontrak will issue warrants to Acuitas, providing 200% warrant coverage.
• The initial exercise price for warrants related to the first $4.5 million in notes is the lesser of $0.36 or the greater of the closing bid price immediately preceding the note issuance or $0.12.
• For subsequent warrants, the exercise price will be the closing bid price immediately preceding the note issuance.
• Existing warrants issued under the previous agreement will be replaced with new warrants having a $0.36 exercise price.
• The conversion price of existing senior secured convertible promissory notes will be adjusted to the lesser of $0.36 or the greater of the closing bid price immediately prior to conversion or $0.12.
• The company is required to seek stockholder approval for the issuance of the Demand Notes, Demand Warrants, and New Keep Well Warrants, as well as the shares upon conversion or exercise of these securities.
• Holders of warrants from the November 2023 public offering have agreed to a waiver, reducing their exercise price to $0.36, with further potential reductions based on the stock's VWAP and note conversion prices.
• A similar waiver was obtained from the holder of warrants from the November 2023 private placement, with the same exercise price adjustments.

Sentiment

Score: 4

Explanation: The document indicates a necessary capital raise, which is positive for the company's immediate financial needs, but the terms, including potential dilution and reliance on investor discretion, introduce significant risks and uncertainties, resulting in a lower sentiment score.

Positives

• The company has secured immediate funding of $1.5 million.
• There is a potential for up to $13.5 million in additional funding.
• The warrant coverage of 200% provides significant potential upside for Acuitas.
• The adjustment of existing warrant exercise prices could be beneficial for warrant holders.
• The conversion price adjustment of existing notes could be beneficial for note holders.

Negatives

• The potential for significant dilution of existing shares due to the issuance of new shares upon conversion of notes and exercise of warrants.
• The company is required to seek stockholder approval for the transactions, which introduces uncertainty.
• The exercise price of the warrants could be significantly lower than the current share price, leading to further dilution.
• The company is reliant on Acuitas's discretion to purchase additional notes.

Risks

• The company's ability to secure the additional $13.5 million in funding is dependent on Acuitas's discretion.
• The issuance of new shares upon conversion of notes and exercise of warrants could significantly dilute existing shareholders.
• The company's stock price could be negatively impacted by the potential for significant dilution.
• The company's ability to obtain stockholder approval for the transactions is not guaranteed.
• The company's financial position could be negatively impacted if the additional funding is not secured.

Future Outlook

The company anticipates securing up to $15 million in total funding through the issuance of Demand Notes, subject to Acuitas's discretion and stockholder approval. The company will also be issuing new warrants and adjusting the terms of existing warrants and notes.

Industry Context

This announcement reflects a common strategy for companies seeking capital, particularly those in the healthcare technology sector. The use of convertible notes and warrants is a typical approach to attract investors while providing flexibility for the company. The need for stockholder approval highlights the importance of corporate governance and transparency in such transactions.

Comparison to Industry Standards

• The use of convertible notes and warrants is a common practice in the biotech and healthcare technology industries, particularly for companies that are not yet profitable or are in a growth phase.
• The 200% warrant coverage is relatively high, suggesting a significant potential upside for the investor, Acuitas, but also a high potential for dilution for existing shareholders.
• The exercise price adjustments for existing warrants are similar to those seen in other financings, aiming to provide some protection to existing warrant holders from the dilutive effects of new issuances.
• The requirement for stockholder approval is standard for transactions that could significantly impact the company's capital structure.
• Compared to other similar financings, the terms of this agreement appear to be relatively favorable to the investor, Acuitas, given the high warrant coverage and the potential for significant exercise price reductions.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Warrant holders from the public and private offerings will have their exercise prices adjusted.
• Note holders will have their conversion prices adjusted.
• Employees may be impacted by the company's financial stability and future prospects.
• Customers and suppliers may be indirectly affected by the company's financial decisions.

Next Steps

• The company will issue the initial Demand Note on April 1, 2024.
• The company will seek stockholder approval for the issuance of the Demand Notes, Demand Warrants, and New Keep Well Warrants.
• The company will issue new warrants to replace existing warrants after stockholder approval.
• The company will adjust the conversion price of existing notes after stockholder approval.
• Acuitas may purchase additional Demand Notes at its discretion.

Key Dates

Keywords

Ontrak, Acuitas Capital, Master Note Purchase Agreement, Demand Notes, Demand Warrants, Keep Well Warrants, Convertible Notes, Stockholder Approval, Dilution, Funding, Warrant Coverage, Exercise Price, Conversion Price